Answers are grounded in this paper and cite their sources.
Glucose has been the cornerstone osmotic agent in peritoneal dialysis (PD) for decades, providing essential ultrafiltration for volume control. However, the substantial daily glucose absorption (100–300g) from PD solutions creates a complex clinical paradox: while enabling life-sustaining therapy, it simultaneously introduces significant metabolic burden and peritoneal membrane damage. This article examines the dual nature of glucose in PD, exploring its essential benefits alongside its well-documented complications, and presents current and emerging strategies for glucose minimisation. With inflammation beginning immediately upon PD initiation rather than developing gradually, glucose-sparing approaches should be considered from treatment commencement, not delayed until complications arise.
No takes yet. Share an insight, caveat, or question.
Jyoti Baharani (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: